NTRK1 and lung adenocarcinoma: C-ros oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements are reported in 1–2% of lung adenocarcinomas and are sensitive to the small-molecule tyrosine kinase inhibitor crizotinib (1,2).